{"preliminary_commentary":{"by_channel":{"x_thread":3,"podcast":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["lapatinib"]],"indication":"HER1 and/or HER2 overexpressing advanced bladder cancer","name":"LaMB","nct_id":"NCT00949455","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=lamb-nct00949455. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"LaMB","arms":[{"description":"Patients receive oral lapatinib ditosylate once daily in the absence of disease progression or unacceptable toxicity.","label":"Arm I","type":"EXPERIMENTAL"},{"description":"Patients receive oral placebo once daily in the absence of disease progression or unacceptable toxicity.","label":"Arm II","type":"PLACEBO_COMPARATOR"}],"collaborators":["GlaxoSmithKline"],"completion_date":null,"conditions":["Bladder Cancer"],"enrollment":{"count":204,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"lapatinib ditosylate","otherNames":["Tykerb","Tyverb"],"type":"DRUG"},{"name":"Placebo","otherNames":[],"type":"OTHER"}],"last_update":"2015-04-15","lead_sponsor":"Queen Mary University of London","official_title":"A Phase II/III, Randomised, Two-Arm, Comparison of Maintenance Lapatinib Versus Placebo After First-Line Chemotherapy in Patients With HER1 and/or HER2 Overexpressing Locally Advanced or Metastatic Bladder Cancer [LaMB]","overall_status":"UNKNOWN","phases":["PHASE2","PHASE3"],"primary_completion_date":{"date":"2015-07","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Progression free survival","timeFrame":"Disease Progression - at least 20% increase in the sum of longest diameters of target lesions."}],"references":[{"citation":"Bellmunt J, Werner L, Bamias A, Fay AP, Park RS, Riester M, Selvarajah S, Barletta JA, Berman DM, de Muga S, Salido M, Gallardo E, Rojo F, Guancial EA, Bambury R, Mullane SA, Choueiri TK, Loda M, Stack E, Rosenberg J. HER2 as a target in invasive urothelial carcinoma. Cancer Med. 2015 Jun;4(6):844-52. doi: 10.1002/cam4.432. Epub 2015 Feb 26.","pmid":"25720673","type":"DERIVED"}],"start_date":{"date":"2009-03"},"study_type":"INTERVENTIONAL","title":"A Double Blind Randomised Study of Lapatinib and Placebo in Metastatic TCC of the Urothelium","url":"https://clinicaltrials.gov/study/NCT00949455"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/lamb-nct00949455"}